COMMUNIQUÉS West-GlobeNewswire

-
Glucotrack Announces Repurchase of Series A Warrants
08/07/2025 -
QHS Healthcare, Powered by QHSLab, Inc. (OTCQB: USAQ), Opens Doors in Miami to Expand Access to Mental Health Services
08/07/2025 -
Highridge to Introduce activL® Lumbar Disc
08/07/2025 -
Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025
08/07/2025 -
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
08/07/2025 -
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
08/07/2025 -
Greenspace Leads Scientific Revival of Ayurveda With New Quantum-Based Approach
08/07/2025 -
Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors
08/07/2025 -
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
08/07/2025 -
PathAI Launches Precision Pathology Network to Advance AI-Powered Pathology
08/07/2025 -
Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials for Type 1 Diabetes
08/07/2025 -
Courtney Caputo Named Chair of the National Board of Directors at the Epilepsy Foundation of America
08/07/2025 -
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
08/07/2025 -
Medicines for Poland lance un avertissement : sans usines pharmaceutiques, aucune guerre ne pourra être gagnée en Europe
08/07/2025 -
Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data
08/07/2025 -
WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause
08/07/2025 -
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
08/07/2025 -
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
08/07/2025 -
Novartis receives approval for first malaria medicine for newborn babies and young infants
08/07/2025
Pages